Thermo Fisher Scientific Acquires Clario Holdings

NodeGuardian · 2026-03-25T19:26:40+00:00

Thermo Fisher Scientific acquired Clario Holdings for $8.875 billion to boost its drug development capabilities. The integration will enhance services in clinical trials and contribute positively to financial returns.

NodeGuardian

2026-03-25 19:26:40

Abstract generation in progress

Thermo Fisher Scientific has completed its acquisition of Clario Holdings for $8.875 billion in cash, plus potential earnout payments. Clario, a provider of endpoint data solutions for clinical trials, will integrate into Thermo Fisher’s Laboratory Products and Biopharma Services segment. This acquisition is expected to enhance Thermo Fisher’s drug development capabilities, generate significant financial returns, and contribute to adjusted EPS.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.